REACH InsightsDanielle Drayton2026-05-20T17:50:49+00:00

REACH Insights

~20% of Dupixent-treated atopic dermatitis patients are refractory to the drug (MARKETVUE® REPORT)

July 27th, 2023|

Less than half of endocrinologists are impressed with Tzield’s ability to delay T1D (MARKETVUE® REPORT)

July 18th, 2023|

There is significant need for efficacious membranous nephropathy treatments for high-risk patients (MARKETVUE® REPORT)

July 18th, 2023|

Spevigo launch going well for Generalized Pustular Psoriasis (MARKETVUE® REPORT)

May 8th, 2023|

~20% of Dupixent-treated atopic dermatitis patients are refractory to the drug (MARKETVUE® REPORT)

Danielle Drayton2023-07-27T15:50:26+00:00July 27th, 2023|

Less than half of endocrinologists are impressed with Tzield’s ability to delay T1D (MARKETVUE® REPORT)

Danielle Drayton2023-07-18T13:22:16+00:00July 18th, 2023|

There is significant need for efficacious membranous nephropathy treatments for high-risk patients (MARKETVUE® REPORT)

Danielle Drayton2023-07-18T13:20:44+00:00July 18th, 2023|

Spevigo launch going well for Generalized Pustular Psoriasis (MARKETVUE® REPORT)

Danielle Drayton2023-05-08T11:49:41+00:00May 8th, 2023|

Previous 678 Next